Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015 Lasa Supergenerics has informed that Meeting of the Board of Directors of the Company is scheduled to be held on Thursday, February 13, 2025, 1. To consider, approve and take on records unaudited financial results of the Company along with the Limited Review Report for the quarter ended on December 31, 2024. 2. To discuss any other matter with the permission of the Chairperson. In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company’s Code of Conduct, the Trading Window shall continue to remain closed till 48 hours after the declaration of the unaudited financial results of the Company for the quarter ended December 31, 2024. This Intimation is also available on the company’s website at www.lasalabs.com and on the website of the stock Exchange at www.bseindia.com and www.nseindia.com.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: